Advertisement
Screener

JASPER THERAPEUTICS, INC. (JSPR) Overview

JASPER THERAPEUTICS, INC. (JSPR) Overview

  • 1 Apr 2026: Period ending 30 Jun 2026; Estimate (m); Actual -0.10; Beat / miss (m).
  • 1 Jan 2026: Period ending 31 Mar 2026; Estimate (m); Actual -0.04; Beat / miss (m).
  • 1 Jul 2025: Period ending 30 Sept 2025; Estimate (m); Actual -1.13; Beat / miss (m).
  • 1 Apr 2025: Period ending 30 Jun 2025; Estimate (m); Actual -1.74; Beat / miss (m).

Stock Price Chart

View more →

Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close

$0.32$0.49$0.76$1.16$1.78$2.732025-09-292026-09-29$0.32$1.13$3.98$13.98$49.10$172.412021-09-292026-09-29$0.32$1.13$3.98$13.98$49.10$172.412020-01-102026-09-29$0.32$1.13$3.98$13.98$49.10$172.412020-01-102026-09-29$0.32$1.13$3.98$13.98$49.10$172.412020-01-102026-09-29

Logarithmic scale. Both lines share the same starting value for the selected range.

Last close
$0.63
Previous close
$0.63
Change
-$0.00
Change (%)
-0.16%
Close date
2026-09-29
Previous close date
2026-09-28
Open
(m)
Day high
(m)
Day low
(m)
Last session volume
(m)
Last session value
(m)
Currency
USD
Price basis
split-adjusted
Volume basis
(m)

Performance

View more →

Cumulative total returns · 2026-09-29

YTD

JSPR
-65.80%
S&P 500
(m)

1 year

JSPR
-74.86%
S&P 500
(m)

3 years

JSPR
-91.06%
S&P 500
(m)

5 years

JSPR
-99.32%
S&P 500
(m)

Earnings trends

View more →

Earnings per share

USD / share · As filed

30 Jun 2026 ○ Estimate (m) ● Actual -0.10

-1.82-1.33-0.84-0.350.1431 Mar 2025: estimate (m); actual -1.4131 Mar 2025(m)30 Jun 2025: estimate (m); actual -1.7430 Jun 2025(m)30 Sept 2025: estimate (m); actual -1.1330 Sept 2025(m)31 Mar 2026: estimate (m); actual -0.0431 Mar 2026(m)30 Jun 2026: estimate (m); actual -0.1030 Jun 2026(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Apr 202630 Jun 2026(m)-0.10(m)(m)
1 Jan 202631 Mar 2026(m)-0.04(m)(m)
1 Jul 202530 Sept 2025(m)-1.13(m)(m)
1 Apr 202530 Jun 2025(m)-1.74(m)(m)
1 Jan 202531 Mar 2025(m)-1.41(m)(m)

31 Dec 2025 ○ Estimate (m) ● Actual -3.95

-10.41-8.44-6.46-4.48-2.5131 Dec 2021: estimate (m); actual -2.6931 Dec 2021(m)31 Dec 2022: estimate (m); actual -10.3331 Dec 2022(m)31 Dec 2023: estimate (m); actual -6.1831 Dec 2023(m)31 Dec 2024: estimate (m); actual -4.8931 Dec 2024(m)31 Dec 2025: estimate (m); actual -3.9531 Dec 2025(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Jan 202531 Dec 2025(m)-3.95(m)(m)
1 Jan 202431 Dec 2024(m)-4.89(m)(m)
1 Jan 202331 Dec 2023(m)-6.18(m)(m)
1 Jan 202231 Dec 2022(m)-10.33(m)(m)
1 Jan 202131 Dec 2021(m)-2.69(m)(m)

Revenue vs. Earnings

USD

No complete retained periods.

No complete retained periods.

Analyst insights

View more →
RatingsBuyHoldSellOther ratingsLast CloseAverage TargetUpsideHigh TargetLow Target
(m)(m)(m)(m)(m)$0.63(m)(m)(m)(m)
Past 12 Months12 Month ForecastLast Close$0.63High(m)Average(m)Low(m)2025-09-292026-09-29

Recent news

View more →

(m)

YouTube videos mentioning JSPR

View more →

(m)

Statistics

View more →

Retained observations as of 2026-11-11; financial period ending (m).

Forward P/E
(m)
PEG ratio · 5-year expected
(m)
Shares held by insiders
(m)
Insider transactions · change (%)
(m)
Shares held by institutions
(m)
Institutional transactions · change (%)
(m)
Diluted EPS · 12 month
(m)
EPS estimate · next quarter
(m)
EPS estimate · next year
(m)
EPS growth · current annual estimate
(m)
EPS growth · next annual estimate
(m)
EPS growth · next 5 years expected
(m)
EPS growth · past 3 years annualized
(m)
EPS growth · past 5 years annualized
(m)
EPS change · 12 months vs prior year
(m)
EPS change · latest quarter vs previous quarter
(m)
Latest earnings report date
(m)
EPS surprise · latest reported quarter
(m)
Net income · 12 month
(m)
Profit margin
(m)
Return on assets · 12 month
(m)
Stock compensation expense · all employees · 12 months
(m)
Named executive and board stock awards · latest fiscal year
(m)
Index membership
(m)
Employees
(m)
IPO date
(m)
Options available
(m)
Shortable
(m)
Analyst recommendation
(m)
Analyst target price
(m)
Price volatility · week
(m)
Price volatility · month
(m)
Average true range · 14 sessions
(m)
Relative strength index · 14 sessions
(m)
Relative volume
(m)
Average daily volume
376.48K
Latest session volume
(m)
Last session value
(m)
30 days ago session value
(m)
1 year ago session value
(m)
Number of trades
(m)
Total return · week
0.32%*
Total return · month
-10.71%*
Total return · quarter
49.02%*
Total return · half year
-40.39%*
Total return · year to date
-65.80%*
Total return · 1 year
-74.86%*
Total return · 3 years
-91.06%*
Total return · 5 years
-99.32%*
Market cap
(m)
Book value per share · latest quarter
(m)
Price / cash · latest quarter
(m)
Enterprise value
(m)
Enterprise value / revenue
(m)
Enterprise value / EBITDA
(m)
Dividend · 12 months per share
(m)
Dividend ex-date
(m)
Next dividend ex-date
(m)
Next dividend amount per share
(m)
Dividend growth · 3 years annualized
(m)
Dividend growth · 5 years annualized
(m)
Revenue · 12 month
(m)
Revenue growth · past 3 years annualized
(m)
Revenue growth · past 5 years annualized
(m)
Revenue change · 12 months vs prior year
(m)
Revenue change · latest quarter vs previous quarter
(m)
Revenue surprise · latest reported quarter
(m)
Levered free cash flow · 12 month
(m)
Debt / equity · latest quarter
(m)
Long-term debt / equity · latest quarter
(m)
Return on equity · 12 month
(m)
Return on invested capital · 12 months
(m)
Previous close
(m)
Latest closing price
(m)
Latest session change (%)
(m)
52-week high
(m)
52-week low
(m)
Price vs 20-session moving average
(m)
Price vs 50-session moving average
(m)
Price vs 200-session moving average
(m)
Float shares
(m)
Short float (%)
(m)
Short ratio (days to cover)
(m)
Short interest (shares)
(m)

Five-year projected P/E and P/S repeat the preceding five-year EPS and revenue CAGR, holding current price and market cap constant. Hover a calculated row for its formula. Net assets = assets − debt − payables − deferred revenue − obligations due within 1 year − obligations due after 1 year.

Holders breakdown

View more →
BreakdownOwnership
(m)Shares held by all insiders
(m)Shares held by institutions
(m)Float held by institutions
(m)Institutions holding shares

Other holders

(m)

View more →

Insider holders

(m)

View more →

Top institutional holders

(m)

View more →

Top mutual fund holders

(m)

View more →

JASPER THERAPEUTICS, INC. Overview

View more →

(m)

(m)

SEC CIK
1788028
Industry (SIC)
2836 Biological Products, (No Diagnostic Substances)
Country of operation
United States
Business address
2200 BRIDGE PKWY SUITE #102, REDWOOD CITY, California, 94065, United States
Fiscal year end
1231
Phone
6505491400

Similar stocks

Stock NameCountryMarket CapPE Ratio
Estrella Immunopharma, Inc. (ESLA)United States$0.020B
BioCardia, Inc. (BCDA)United States$0.016B
DYADIC INTERNATIONAL INC (DYAI)United States$0.016B
Passage BIO, Inc. (PASG)United States$0.015B-0.43
Pluri Inc. (PLUR)$0.014B
INTENSITY THERAPEUTICS, INC. (INTS)United States$0.013B-1.08
BRAINSTORM CELL THERAPEUTICS INC. (BCLI)United States$0.013B-1.05
IN8BIO, INC. (INAB)United States$0.012B-0.76
Senti Biosciences Holdings, Inc. (SNTI)United States$0.011B-0.70
CEL SCI CORP (CVM)United States$0.030B-0.81